Scinai Immunotherapeutics (SCNI)

Executive Summary

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a small-cap biopharmaceutical company based in Jerusalem, Israel, specializing in antibody-based therapies for infectious diseases and autoimmune disorders. The company differentiates itself through its current Good Manufacturing Practice (cGMP) biologics facility, which supports both internal development and contract development and manufacturing organization (CDMO) services. With a valuation of approximately $2 million and limited public pipeline details, Scinai faces high execution risk but holds potential upside from its manufacturing capabilities and therapeutic programs. The company's strategy involves advancing proprietary research while leveraging its facility to generate near-term CDMO revenue, positioning it as a dual-focused entity in the immunotherapy space.

Upcoming Catalysts (preview)

• Q3 2026CDMO Service Contract Wins50% success
• H1 2027Clinical Milestone for Autoimmune Program30% success
• H2 2026Partnership or Licensing Agreement for Infectious Disease Candidate40% success